Bajaj FinServ (Rs.436.00) (Code : 532978)
: Bajaj Finserv is in the financial lending business. Its offers loans for Bajaj Auto Two Wheelers under the name of Bajaj Finance Ltd. It offers Consumer Durable Loans, Personal Loans, Loan Against Property, Small Business Loans, Construction Equipment Loans, Loan Against Securities and Insurance Services under the name of Bajaj Finserv Lending. Bajaj FinServhas received approval from the capital markets regulator SEBI for setting up mutual fund business and is likely to enter the fray by end-2012. On financial front, the company is doing well. Its second quarter total income increased by 52% and its net profit jumped by 128%. Also, its operationg pfrofit also improved by 96 per cent. For H1, its income has jumped by 123% and net profit by 112%. All in all, this company is worth investing. This is best time to enter into this counter. It will give you at least 20 per cent return in the year 2012.
HDFC Bank (Rs.437.00) (Code : 500180)
: HDFC Bank is one of the strongest bank as far as the fundamentals are concenred. It is a compelling buy for
the new year as it is safe also in this time of uncertainty. It is a consistent performer. Its earnings have grown
30 per cent for the last 38 quarters. It is a big achievement to maintain such a higher growth for such a long period consitently. Its advances have grown even in the difficult days for the banking sector. For the Q2, its advances grew by 26 per cent to Rs. 190000 crore. Also, its depositsmgrowth was at 18 per cent. Its NIM
has been improving. NIM was 4.1 per cent in the second quarter for the current year. Besides all these, its
management is best and it is able to withstand across all the economic cycles. That’s the biggest positive for
this banking counter. It is a definite buy. Buy more at every decline, if any.
the new year as it is safe also in this time of uncertainty. It is a consistent performer. Its earnings have grown
30 per cent for the last 38 quarters. It is a big achievement to maintain such a higher growth for such a long period consitently. Its advances have grown even in the difficult days for the banking sector. For the Q2, its advances grew by 26 per cent to Rs. 190000 crore. Also, its depositsmgrowth was at 18 per cent. Its NIM
has been improving. NIM was 4.1 per cent in the second quarter for the current year. Besides all these, its
management is best and it is able to withstand across all the economic cycles. That’s the biggest positive for
this banking counter. It is a definite buy. Buy more at every decline, if any.
Pfizer (Rs. 1099.00)(Code : 500680) :
One of the highest spenders in pharmaceutical R&D globally, Pfizer has made clinical research investments of US$ 6.05million (November 2009) in India.Two of Pfizer India's brands- Corex (Cough Formulation) and Becosules(Multivitamin)- continue to rank among the Top 10 pharmaceutical drug brands. Pfizer has disclosed a marginalrise in standalone net profit for the quarter ended Sep 2011. During the quarter, the profit of the company surged 10.62% to Rs.469.90 million from Rs.424.80 million. At the current market price of Rs.1185.00, the stockis trading at 17.06 x FY12E and 14.67 x FY13E respectively. Earning per share (EPS) of the company for theearnings for FY12E and FY13E is seen at Rs.69.46 and Rs.80.80 respectively.On the basis of EV/ EBITDA, the stock trades at 11.01 x for FY12E and 9.50 x for FY13E. Price to Book Value of the stock is expected to be at 2.58 x and 2.19 x respectively for FY12E and FY13E. As the stock is trading at much discount to its 52 week high of Rs. 1600 plus, it is worth accumulating.
One of the highest spenders in pharmaceutical R&D globally, Pfizer has made clinical research investments of US$ 6.05million (November 2009) in India.Two of Pfizer India's brands- Corex (Cough Formulation) and Becosules(Multivitamin)- continue to rank among the Top 10 pharmaceutical drug brands. Pfizer has disclosed a marginalrise in standalone net profit for the quarter ended Sep 2011. During the quarter, the profit of the company surged 10.62% to Rs.469.90 million from Rs.424.80 million. At the current market price of Rs.1185.00, the stockis trading at 17.06 x FY12E and 14.67 x FY13E respectively. Earning per share (EPS) of the company for theearnings for FY12E and FY13E is seen at Rs.69.46 and Rs.80.80 respectively.On the basis of EV/ EBITDA, the stock trades at 11.01 x for FY12E and 9.50 x for FY13E. Price to Book Value of the stock is expected to be at 2.58 x and 2.19 x respectively for FY12E and FY13E. As the stock is trading at much discount to its 52 week high of Rs. 1600 plus, it is worth accumulating.
No comments:
Post a Comment